The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Annals of Neurology

• Publication date

  2004-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ana.10795PMID 14755719
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop

  2006cited by this paper
• Erratum: Mutations in NR4A2 associated with familial Parkinson disease (Nature Genetics (2003) 33 (85-89))

  2003cited by this paper
• Accumulation of Phosphorylated α‐Synuclein in Aging Human Brain

  2003cited by this paper
• Accumulation of phosphorylated alpha-synuclein in aging human brain.

  2003cited by this paper
• Mutations in NR4A2 associated with familial Parkinson disease

  2003cited by this paper
• A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1

  2002cited by this paper
• Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease.

  2002cited by this paper
• Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred.

  2002cited by this paper
• Effect of Mutant α-Synuclein on Dopamine Homeostasis in a New Human Mesencephalic Cell Line*

  2002cited by this paper
• Familial diffuse Lewy body disease, eye movement abnormalities, and distribution of pathology.

  2002cited by this paper
• Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand

  2002cited by this paper
• Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors.

  2002cited by this paper
• Familial dementia with Lewy bodies: clinicopathologic analysis of two kindreds.

  2002cited by this paper
• Progressive supranuclear palsy and tau hyperphosphorylation in a patient with a C212Y parkin mutation

  2002cited by this paper
• Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism

  2002cited by this paper
• Concurrence of α-synuclein and tau brain pathology in the Contursi kindred

  2002cited by this paper
• Formation and Removal of α-Synuclein Aggregates in Cells Exposed to Mitochondrial Inhibitors*

  2002cited by this paper
• Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36.

  2001cited by this paper
• Cortical Lewy body pathology in the diagnosis of dementia

  2001cited by this paper
• Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36.

  2001cited by this paper
• Synucleinopathies: clinical and pathological implications.

  2001cited by this paper
• Familial Parkinson's disease and related conditions. Clinical genetics.

  2001cited by this paper
• Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease.

  2001cited by this paper
• Induction of alpha-synuclein aggregation by intracellular nitrative insult.

  2001cited by this paper
• Induction of α-Synuclein Aggregation by Intracellular Nitrative Insult

  2001cited by this paper
• Distinctive neuropathology revealed by α-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p

  2000cited by this paper
• Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

  2000cited by this paper
• [Dementia with Lewy bodies].

  2000cited by this paper
• Mice Lacking a-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine

  2000cited by this paper
• Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.

  2000cited by this paper
• Clinical and quantitative pathologic correlates of dementia with Lewy bodies

  1999cited by this paper
• The genetics of disorders with synuclein pathology and parkinsonism.

  1999cited by this paper
• Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease.

  1999cited by this paper
• Familial aggregation of Parkinson’s disease

  1999cited by this paper
• Report of the second dementia with Lewy body international workshop

  1999cited by this paper
• Familial dementia with Lewy bodies (DLB).

  1999cited by this paper
• A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor.

  1999cited by this paper
• Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

  1998cited by this paper
• Sequencing of the α-Synuclein Gene in a Large Series of Cases of Familial Parkinson's Disease Fails to Reveal any Further Mutations

  1998cited by this paper
• Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson’s disease

  1998cited by this paper
• The ubiquitin pathway in Parkinson's disease

  1998cited by this paper
• Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

  1998cited by this paper
• Mutation in the tau gene in familial multiple system tauopathy with presenile dementia.

  1998cited by this paper
• Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17

  1998cited by this paper
• AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease

  1998cited by this paper
• A susceptibility locus for Parkinson's disease maps to chromosome 2p13

  1998cited by this paper
• Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

  1997cited by this paper
• Familial parkinsonism, dementia, and lewy body disease: Study of family G

  1997cited by this paper
• Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

  1997cited by this paper
• Clinical features of familial diffuse Lewy body disease.

  1997cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)

  1996cited by this paper
• Neocortical Lewy Body Counts Correlate with Dementia in the Lewy Body Variant of Alzheimer's Disease

  1996cited by this paper
• Mapping of a Gene for Parkinson's Disease to Chromosome 4q21-q23

  1996cited by this paper
• Dementia with Lewy bodies

  1996cited by this paper
• Clinical genetic analysis of Parkinson's disease in the contursi kindred

  1996cited by this paper
• Clinical characteristics of a family with chromosome 17‐linked disinhibition‐dementia‐ parkinsonism‐amyotrophy complex

  1994cited by this paper
• Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22.

  1994cited by this paper
• Autosomal dominant parkinsonism with benign course and typical Lewy-body pathology.

  1993cited by this paper
• Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

  1992cited by this paper
• A large kindred with autosomal dominant Parkinson's disease

  1990cited by this paper
• Presenile dementia with Alzheimer-, Pick- and Lewy-body changes

  1976cited by this paper

• SNCA (α-synuclein) H50Q mutation reveals distinct neurodegenerative patterns and adaptive responses in Parkinson's disease Drosophila model.

  2026cites this paper
• An update on the monogenic causes of Parkinson's disease: Impact on patient stratification and personalised medicine.

  2026cites this paper
• Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease.

  2026cites this paper
• Impact of Gender and Race on Gastrointestinal Diseases in Patients With Parkinson's Disease: A Nationwide Analysis

  2026cites this paper
• In vitro-prepared A30P alpha-synuclein fibrils adopt the conserved and disease-relevant Greek key fold

  2026cites this paper
• Bases moléculaires de la maladie de Parkinson

  2026cites this paper
• Quantifying the Acute Toxicity of Alpha-Synuclein Membrane-Accumulation in a Cell-Based Assay

  2026cites this paper
• Degradation of alpha-synuclein/SNCA mRNA by RNautophagy.

  2026cites this paper
• Synaptic aging and neurodegeneration: the role of synaptic vesicle dynamics and neurotransmitter imbalance

  2026cites this paper
• Multifaceted performances of α-synuclein in health and neurological diseases.

  2026cites this paper
• When Proteins Go MAD—Misfolded, Amplified, Detected: Advances in α-Synuclein Pathophysiology and RT-QuIC Detection

  2026cites this paper
• Oxidative modification of methionine residue in α-synuclein by dopamine induces cellular vulnerability, oligomerization and secretion of α-synuclein

  2025cites this paper
• Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies

  2025cites this paper
• Artificial miRNA mediated reduction of SNCA for the treatment of α-synucleinopathies.

  2025cites this paper
• Unfolding Sequence-Specific Enigma in Monomeric α-Synuclein: Implications for Parkinson's Disease.

  2025cites this paper
• A high-content imaging workflow to screen for molecules that reduce cellular uptake of α-synuclein preformed fibrils

  2025cites this paper
• Drug discovery and development for Parkinson’s disease: are preclinical models good enough?

  2025cites this paper
• Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?

  2025cites this paper
• Identification of small molecule dimethyoxyphenyl piperazine inhibitors of alpha-synuclein fibril growth

  2025influential citation
• The quest for Parkinson’s disease biomarkers: traditional and emerging multi-omics approaches

  2025cites this paper
• Sequencing of α-synuclein Intrinsically Disordered Protein in MoS2 Nanopores

  2025cites this paper
• Exploring the environmental sources of Parkinson’s disease and recent nanotechnological interventions in animal Parkinson models

  2025cites this paper
• A novel alpha-synuclein G14R missense variant is associated with atypical neuropathological features

  2025cites this paper
• Connectivity of the adult human brain with sequential neurogenesis of circuits and transcriptomics signatures

  2025cites this paper
• Parkinson disease is a fatty acidopathy

  2025cites this paper
• Precision Interdiction of α-Synuclein Folding Pathways by Molecular Tweezers.

  2025cites this paper
• On the transient interactions of α-synuclein in different dimensions

  2025cites this paper
• High-resolution Cryo-EM Structure Determination of a-Synuclein—A Prototypical Amyloid Fibril

  2025cites this paper
• The novel p.A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease

  2025cites this paper
• Molecular Insights into α-Synuclein Fibrillation: A Raman Spectroscopy and Machine Learning Approach

  2025cites this paper
• Common SNCA Genetic Variants and Parkinson’s Disease Risk: A Systematic Review and Meta-Analysis

  2025cites this paper
• Mechanism of flavonoid myricetin modulated aggregation in α-Synuclein and its familial mutants E46K and A30P.

  2025cites this paper
• Stochastic Misfolding Drives the Emergence of Distinct α-Synuclein Strains

  2025cites this paper
• Cognitive Decline in Parkinsonism: From Clinical Phenotypes to the Genetic Background

  2025cites this paper
• Development of In Vitro Parkinson's Disease Model Mediated by MPP+ and α‐Synuclein Using Wharton's Jelly Mesenchymal Stem Cells

  2025cites this paper
• Glycine-to-aspartic acid mutation at codon 51 in Snca disrupts the synaptic localisation of α-synuclein and enhances its propensity for synucleinopathy

  2025cites this paper
• α-Synuclein-Assembled Synaptic Vesicle Pools at the Presynaptic Terminal: A Study of α-Synuclein Function Using a Novel Mouse Model

  2025cites this paper
• Identification of Small Molecule Dimethyoxyphenyl Piperazine Inhibitors of Alpha-Synuclein Fibril Growth

  2025cites this paper
• α-Synuclein Drives SNARE-Dependent Tubular Remodeling of Vesicles.

  2025cites this paper
• Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein

  2025cites this paper
• Adenine bolsters the monomeric conformations of the intrinsically disordered A53T mutant of α-Synuclein protein

  2025cites this paper
• Zn2+ Binding Shifts the Conformational Ensemble of α‑Synuclein Monomers toward Accelerated Amyloid Formation

  2025cites this paper
• Metabolic manifestations of Parkinson’s disease in cell models derived from induced pluripotent stem cells

  2025cites this paper
• Autophagy Dysfunction in iPSCs-Derived Neurons and Midbrain Organoids Carrying a SNCA Triplication

  2025cites this paper
• A30P and A30G Mutations in α-Synuclein Promote Metastable Long-Lived Aggregates with Distinct Structural Responses to EGCG.

  2025cites this paper
• Molecular Dynamics Study of α-Synuclein Domain Deletion Mutant Monomers

  2025cites this paper
• α-Synuclein Iron-Responsive-Element RNA and Iron Regulatory Protein Affinity Is Specifically Reduced by Iron in Parkinson’s Disease

  2025cites this paper
• Sex-dependent immune activation shapes disease progression in a model of Parkinson’s disease

  2025cites this paper
• Cryo-EM structure of α-Synuclein Fibrils Harboring the Dementia with Lewy Bodies–Associated E83Q Mutation

  2025cites this paper
• STIP1/HOP Promotes the Formation of Cytotoxic α-Synuclein Oligomers

  2025cites this paper
• Alpha-synuclein pathology and Parkinson’s disease-related olfactory dysfunctions: an update on preclinical models and therapeutic approaches

  2025cites this paper
• Rationally designed peptides inhibit the formation of α-synuclein fibrils and oligomers.

  2025cites this paper
• A novel alpha-synuclein K58N missense variant in a patient with Parkinson’s disease

  2025cites this paper
• Limitations and Applications of Rodent Models in Tauopathy and Synucleinopathy Research

  2025cites this paper
• Illuminating synucleinopathies: Advances in α-synuclein PET tracer development for in vivo neuroimaging

  2025cites this paper
• Neuropathology in genetic Parkinson's disease: a focused review of pathological and clinical findings.

  2025cites this paper
• Alpha-synuclein null mutation exacerbates the phenotype of a model of Menkes disease in female mice

  2025cites this paper
• In-silico study of – 39 phytochemicals targeted against micelle-bound and Parkinson’s diseased patient’s ‘α-Synuclein’

  2025cites this paper
• G6PD deficiency triggers dopamine loss and the initiation of Parkinson's disease pathogenesis.

  2025cites this paper
• DOPAC as a modulator of α-Synuclein and E46K interactions with membrane: Insights into binding dynamics.

  2025cites this paper
• Alpha synuclein and inflammaging

  2025cites this paper
• Targeting the Interplay Between Autophagy and the Nrf2 Pathway in Parkinson’s Disease with Potential Therapeutic Implications

  2025cites this paper
• Aging, cellular senescence and Parkinson's disease

  2025cites this paper
• Sulfamerazine as a Potential Modulator against α-Synuclein Aggregation and Associated Toxicity.

  2025cites this paper
• Outlook of SNCA (α-synuclein) transgenic fly models in delineating the sequel of mitochondrial dysfunction in Parkinson's disease.

  2025cites this paper
• How is the Amyloid Fold Built? Polymorphism and the Microscopic Mechanisms of Fibril Assembly.

  2025cites this paper
• Autoantibodies against α-synuclein inhibit its aggregation and cytotoxicity.

  2025cites this paper
• Bridging Mechanical Properties with Atomic Structures of Polymorphic α‐Synuclein Fibrils by Single‐Molecule Analysis and Molecular Dynamics Simulations

  2025cites this paper
• α‐Synuclein Pathology Spreads in a Midbrain–Hindbrain Assembloid Model

  2025cites this paper
• Targeted degradation of α-synuclein prevents PFF-induced aggregation

  2025cites this paper
• Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations

  2025cites this paper
• Engineered sequestrins inhibit aggregation of pathogenic alpha-synuclein mutants

  2025cites this paper
• Exploring α-Syn’s Functions Through Ablation Models: Physiological and Pathological Implications

  2025cites this paper
• Molecular insights and risk estimating computational database for Parkinson’s disease (PDASD)

  2025cites this paper
• SNCA-targeted epigenome therapy for Parkinson’s disease alleviates pathological and behavioral perturbations in a mouse model

  2025cites this paper
• Comparative assessment of binding and functional differences of clinical antibodies targeting α-synuclein in cellular models of Parkinson's disease.

  2025cites this paper
• Non‐human primate models of Parkinson's disease: Decoding pathogenesis and advancing therapies

  2025cites this paper
• Oxidation-induced destabilization of polymorphic α-synuclein fibrils: insights from molecular dynamics

  2025cites this paper
• The Yeast Parkinson’s Disease Model Exhibits An Increase in Peroxisome Number Independent of the Division Proteins Vps1 and Dnm1

  2025cites this paper
• Isobavachalcone inhibits α-synuclein fibrillogenesis and its Parkinson's disease variants, disassembles the mature fibrils and alleviates cellular toxicity.

  2025cites this paper
• Expression of human A53T alpha-synuclein without endogenous rat alpha-synuclein fails to elicit Parkinson’s disease-related phenotypes in a novel humanized rat model

  2025cites this paper
• Astrocyte alterations in α-synucleinopathies

  2025cites this paper
• Evidence of a novel α-synuclein strain isolated from a Parkinson’s disease with dementia patient sample

  2025cites this paper
• MicroRNAs and synaptic dysfunction in Parkinson’s disease

  2025cites this paper
• A Novel α‐Synuclein K58N Missense Variant in a Patient with Parkinson's Disease

  2025cites this paper
• Stabilizing a Native Fold of Alpha-Synuclein with Short Helix-Constrained Peptides

  2025cites this paper
• Large-scale visualization of α-synuclein oligomers in Parkinson's disease brain tissue.

  2025cites this paper
• Rising Stars: Molecular Mechanisms and Chemical Interventions of α-Synuclein Amyloid Aggregation in Parkinson's Disease.

  2025cites this paper
• Brain region-specific and systemic transcriptomic alterations in a human alpha-synuclein overexpressing rat model

  2025cites this paper
• Effects of Ghrelin Hormone on Alzheimer’s and Parkinson’s Disease: A Systematic Review of the Existing Literature

  2025cites this paper
• Pathological α-synuclein elicits granulovacuolar degeneration independent of tau

  2024cites this paper
• A Structural Proteomics Exploration of Synphilin-1 and Alpha-Synuclein Interaction in Pathogenesis of Parkinson’s Disease

  2024cites this paper
• A-synuclein prion strains differentially adapt after passage in mice

  2024cites this paper
• α-Synuclein pathology as a target in neurodegenerative diseases

  2024cites this paper
• The Role of Microglia and Astrocytes in the Pathomechanism of Neuroinflammation in Parkinson's Disease-Focus on Alpha-Synuclein.

  2024cites this paper
• Alpha-Synuclein and Microglia in Parkinson’s Disease: From Pathogenesis to Therapeutic Prospects

  2024cites this paper
• Overexpression of α-synuclein in PDF neurons alters sleep-wake pattern by regulating lipid metabolism in Drosophila.

  2024cites this paper
• The potential of natural products to inhibit abnormal aggregation of α-Synuclein in the treatment of Parkinson’s disease

  2024cites this paper
• Exploring the Interaction of Human α-Synuclein with Polyethylene Nanoplastics: Insights from Computational Modeling and Experimental Corroboration.

  2024cites this paper
• A novel function for α-synuclein as a regulator of NCK2 in olfactory bulb: implications for its role in olfaction

  2024cites this paper